Petros Grivas

Petros Grivas

Medical Oncologist

Genitourinary Oncology

Fred Hutch Cancer Center

Location USA, Seattle

Linkedin

X

Dr. Petros Grivas is a board-certified medical oncologist and internationally recognized expert in genitourinary (GU) cancers, currently serving as Professor in the Clinical Research Division at Fred Hutch Cancer Center and Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle. He is the Clinical Director of the GU Cancers Program at the University of Washington and holds roles as Medical Director of Local/Regional Outreach and Medical Director of the International Program at Fred Hutch. Born and trained in Greece, Dr. Grivas earned his MD and PhD from the University of Patras before completing residency at Drexel University/Hahnemann University Hospital and fellowship in Hematology/Oncology at the University of Michigan. He played a central role in clinical trials that led to FDA approvals of new drugs for urothelial/bladder cancer, is a leader in checkpoint inhibitor trials in GU malignancies, and is considered a global thought leader who lectures internationally and pursues active community outreach.

Current Positions

  • Professor, Clinical Research Division, Fred Hutch Cancer Center, Seattle, Washington, January 2018–present
  • Medical Director, Local/Regional Outreach, Fred Hutch Cancer Center
  • Medical Director, International Program, Fred Hutch Cancer Center
  • Professor, Division of Hematology and Oncology, University of Washington School of Medicine, January 2018–present
  • Clinical Director, Genitourinary Cancers Program, University of Washington

Education

  • MD, University of Patras School of Medicine, Greece, 1999–2007
  • PhD, Medical Oncology, University of Patras School of Medicine, Greece, 2009
  • Residency, Internal Medicine, Hahnemann University Hospital / Drexel University College of Medicine, Philadelphia, Pennsylvania, June 2007–June 201
  • Fellowship, Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, 2010–2013

Professional Experience

  • Clinical Lecturer, Hematology/Oncology, University of Michigan, July 2013–July 2014
  • Staff Physician, Hematology/Oncology, Cleveland Clinic, July 2014–December 2017
  • Professor, Fred Hutch Cancer Center and University of Washington School of Medicine, January 2018–present
  • Clinical Director, GU Cancers Program, University of Washington, January 2018–present

Research Activity

  • Urothelial and bladder cancer: Clinical and translational research in urothelial carcinoma spanning diagnosis, staging, chemotherapy, immunotherapy, targeted therapy, and precision oncology; played a central role in clinical trials leading to FDA approvals of new drugs for urothelial cancer; ongoing leadership of early- and late-phase trials including the INTerpath-011 study of intismeran autogene plus BCG in high-risk NMIBC and the ECOG ACRIN EA8192 study of neoadjuvant gemcitabine/durvalumab in cisplatin-ineligible upper tract urothelial carcinoma
  • UNITE study: Key investigator in the multi-institutional retrospective UNITE collaborative study, which has produced a large body of real-world evidence on enfortumab vedotin (EV) and pembrolizumab outcomes in advanced urothelial carcinoma, including analyses of FGFR3 alterations, HER2/ERBB2 status, prior ICI exposure, dose reductions, treatment-related adverse events, and erdafitinib sequencing
  • Biomarkers and precision oncology: Comprehensive genomic profiling (CGP) studies of advanced urothelial bladder cancer including ERBB3 alterations, MTAP loss via liquid biopsy, FGFR3 detection in liquid biopsies, and N-RAS transcript levels in muscle-invasive bladder cancer; co-investigator on genomic landscape studies across multiple GU tumor types including VHL wild-type clear cell renal cell carcinoma
  • Immune checkpoint inhibitors and irAE management: Research on checkpoint inhibitor outcomes and toxicity management in GU cancers; co-author on steroid-sparing strategies for immune-related adverse events; JAVELIN Bladder 100 avelumab first-line maintenance analyses
  • Molecular classification of urothelial carcinoma: Co-investigator in multi-omic profiling studies defining molecular subtypes of urothelial carcinoma with implications for precision therapy
  • Regional node-positive bladder cancer and muscle-invasive disease: Co-author on International Bladder Cancer Group (IBCG) consensus recommendations for optimal management of muscle-invasive bladder cancer and regional node-positive disease; contributed to consensus conference on endpoints for bladder-sparing perioperative trials
  • Advanced urologic cancer consensus: Panel member, 2025 Advanced Urologic Cancer Consensus Conference (AUC3) for expert consensus on management of renal cell and urinary tract cancers (CA: A Cancer Journal for Clinicians, 2025)
  • Community outreach and clinical trial equity: Co-investigator on analysis of research nurse clinical trial pre-screening impact on enrollment of underrepresented populations in GU oncology trials; Medical Director of Local/Regional Outreach and International Program at Fred Hutch

Areas of Specialization

  • Medical oncology — genitourinary cancers
  • Bladder and urothelial carcinoma (non-muscle-invasive, muscle-invasive, metastatic)
  • Renal cell carcinoma
  • Prostate cancer
  • Testicular cancer
  • Immune checkpoint inhibitors in GU malignancies
  • Antibody-drug conjugates in urothelial cancer
  • Comprehensive genomic profiling and biomarkers of response
  • Liquid biopsy in bladder cancer (MTAP loss, FGFR3 detection)
  • Molecular classification of urothelial carcinoma
  • FGFR3-targeted therapy
  • Clinical trial design and leadership in GU oncology
  • Community outreach and equitable clinical trial enrollment
  • International oncology and program leadership

Publications

Dr. Grivas has authored and co-authored more than 821 publications. A selection of his most recent publications from the provided materials is listed below.

Kulkarni GS, Bepple J, Lee D, Grivas P, et al. “Comparative effectiveness of gemcitabine intravesical system vs real-world intravesical chemotherapy in BCG-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ: an indirect treatment comparison using an external control group.” The Journal of Urology, May 2026.

van Creij N, Tymoszuk P, Handle F, Grivas P, Pichler R, et al. “Multi-omic profiling identified three molecular clusters in urothelial carcinoma: A path towards clinical precision.” Cancer Research 86(7 Suppl):Abstract nr 6869, AACR 2026.

Kim D, Ged Y, Grivas P, Zakharia Y, et al. “Association Between Proto-Oncogene N-RAS Transcript Level and Overall Survival in Node-Negative Muscle-Invasive Bladder Cancer.” Clinical Genitourinary Cancer, April 2026.

Mercinelli C, Pavlick DC, Grivas P, Necchi A, et al. “Detecting MTAP loss in liquid biopsies from patients with clinically advanced urothelial bladder cancer.” Journal of Clinical Oncology 44(Abstract 819), March 2026.

Blinka SM, Pavlick DC, Graf RP, Grivas P, et al. “ERBB3-altered clinically advanced urothelial bladder cancer: Genomic landscape study and therapeutic possibilities.” Journal of Clinical Oncology 44(Abstract 799), March 2026.

Bakaloudi DR, Makrakis D, Jindal T, Grivas P, et al. “Prognosis of patients with synchronous vs metachronous metastatic or locally advanced urothelial carcinoma.” Journal of Clinical Oncology 44(Abstract 695), March 2026.

Sager RA, Grivas P, Agarwal N, Bratslavsky G, et al. “VHL wild-type clinically advanced clear cell renal cell carcinoma: A genomic landscape study.” Journal of Clinical Oncology 44(Abstract 533), March 2026.

van Creij N, Tymoszuk P, Handle F, Grivas P, Pichler R, et al. “Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy.” Clinical and Translational Medicine, March 2026.

Hoffman-Censits J, Chu X, Margulis V, Grivas P, et al. “ECOG ACRIN EA8192 cohort C: A phase II trial of neoadjuvant gemcitabine/durvalumab in patients with high grade upper tract urothelial carcinoma ineligible for cisplatin-based chemotherapy.” Journal of Clinical Oncology 44(Abstract 749), March 2026.

Li R, Kamat AM, Necchi A, Grivas P, et al. “Intismeran autogene plus BCG versus BCG alone for high-risk non-muscle-invasive bladder cancer: The phase 2 INTerpath-011 study.” Journal of Clinical Oncology 44(TPS882), March 2026.

Pichler R, Subiela JD, Scilipoti P, Grivas P, et al. “Regional Node-positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings.” European Urology, January 2026.

Talwar V, Grivas P, Aragon-Ching JB, Powles T, et al. “Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Patient-Reported Outcomes in the Phase 3 JAVELIN Bladder 100 Trial.” Indian Journal of Medical and Paediatric Oncology, February 2026.

Talwar V, Grivas P, Park SH, Powles T, et al. “Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma: Conditional Survival and Long-Term Safety in the JAVELIN Bladder 100 Phase 3 Trial.” Indian Journal of Medical and Paediatric Oncology, February 2026.

McKay R, Pal S, Xie W, Choueiri TK, Grivas P, et al. “Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.” CA: A Cancer Journal for Clinicians, December 2025.

Meeks J, Lin D, Raymundo E, Grivas P, et al. “Physician experiences with TAR-200 in high-risk non-muscle invasive bladder cancer: A qualitative study of SUNRISE trial investigators.” Poster, December 2025.

Powles T, Tagawa ST, Vulsteke C, Grivas P, et al. “A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract.” Future Oncology, November 2025.

Paras G, Alipour E, Arora S, Nadal Rios R, Grivas P, et al. “Delineating the role of growth differentiation Factor 15 (GDF-15) in advanced bladder and upper tract urinary cancers: University of Washington rapid autopsy program cohort.” Journal for ImmunoTherapy of Cancer, November 2025.

Necchi A, Galsky M, Dizman N, Kamat AM, Grivas P, et al. “End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.” Journal of Clinical Oncology 43(29):3334–3346, September 2025.

Perez Valderrama B, Grivas P, Tsiatas M, Hoffman-Censits J, et al. “JAVELIN bladder medley phase II trial of avelumab plus sacituzumab govitecan vs avelumab monotherapy as first-line maintenance treatment for advanced urothelial carcinoma: subgroup analyses based on metastatic sites.” Annals of Oncology, September 2025.

All information is sourced from publicly available materials.